India Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

India's diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices such as insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices including self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.

India Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

India Diabetes Drugs and Devices Market Size

India Diabetes Drugs and Devices Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 3.00 %

Major Players

India Diabetes Drugs and Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of India Diabetes Drugs and Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

India Diabetes Drugs and Devices Market Analysis

The India Diabetes Drugs and Devices Market is expected to register a CAGR of greater than 3% during the forecast period.

In India, the COVID-19 outbreak began nearly two years ago and has increased by nearly 25%. With over 80 million diabetics, India is called the Diabetes Capital. COVID-19 is a viral infection that causes various inflammatory responses and is associated with several recurring and emerging health problems, including hypoxia, wasting, weight loss, hair loss, myocarditis, and thyroid problems. Increase. However, diabetes is one of the most common side effects of infections. Anoop Misra, a senior endocrinologist in Delhi, observed the prevalence of new-onset diabetes and thyroid dysfunction in patients with COVID-19 in all countries; He said the explanations included the severe effects of a cytokine surge (the strong immune responses reported in certain COVID-19 patients) and some development of autoimmunity (the body's immune system goes awry and when it affects the tissues and organs of the body), it was speculated that it might be included.

A review of literature from around the world finds that metformin is used in various ways in the early stages of diabetes. Sharma et al. found a changing trend in 55% of metformin-treated individuals. The fraction of individuals on metformin remains stable from 0 to 20 years of diabetes. The proportion of sulfonylurea and dipeptidyl peptidase-4 inhibitors (DPP4i) increases from 23.12% and 22.5% in 0-5 years of diabetes to 70.77% and 60% in 10-15 years of diabetes. Following that, the proportion of sulfonylurea and DPP4i remains constant. As the use of sulfonylureas and DPP4i reaches a plateau, insulin and sodium/glucose cotransporter two inhibitors increase. From 5 to 10 years of diabetes duration to 20+ years of diabetes duration, the proportion of alpha-glucosidase inhibitors increases somewhat. Thiazolidinediones and glucagon-like peptide-1 receptor agonists have a small proportion in contemporary practice and the given patient population.

Thus, the above factors are expected to drive the market growth over the forecast period.

India Diabetes Drugs and Devices Industry Overview

Manufacturers have always innovated to outlive in the industry. Big firms as an example Abbott and Medtronic have made abundant mergers, acquisitions, and partnerships to attain industry dominance whereas adhering to biological development techniques. The manufacturers of insulin delivery tools are spending substantial amounts on the R&D of the tools. For example, Novo Nordisk partnered with Abbott Diabetes Care, that may additionally aid to enable insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness trappings well qualified to the FreeStyle Libre portfolio of cosmetics.

India Diabetes Drugs and Devices Market Leaders

  1. Medtronics

  2. Roche

  3. NovoNordisk

  4. Sanofi

  5. Omnipod

  6. *Disclaimer: Major Players sorted in no particular order
India Diabetes Drugs And Devices Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

India Diabetes Drugs and Devices Market News

  • November 2022: AstraZeneca India gets approval to market the anti-diabetes drug Dapagliflozin. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD).
  • March 2022: Medtronic India launched the MiniMed 780G, a next-generation closed-loop insulin pump system. The MiniMed 780G system is a next-generation closed-loop insulin pump system for treating type-1 diabetes in people aged 7-80 years.

Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Dynamics
    • 4.2.1 Market Drivers
    • 4.2.2 Market Restraints
  • 4.3 Porter's Five Forces Analysis
    • 4.3.1 Bargaining Power of Suppliers
    • 4.3.2 Bargaining Power of Consumers
    • 4.3.3 Threat of New Entrants
    • 4.3.4 Threat of Substitute Products and Services
    • 4.3.5 Intensity of Competitive Rivalry

5. Market Segmentation (Market Size by Value - USD)

  • 5.1 Devices
    • 5.1.1 Monitoring Devices
    • 5.1.1.1 Self-monitoring Blood Glucose Devices
    • 5.1.1.2 Continuous Blood Glucose Monitoring
    • 5.1.2 Management Devices
    • 5.1.2.1 Insulin Pump
    • 5.1.2.2 Insulin Syringes
    • 5.1.2.3 Insulin Cartridges
    • 5.1.2.4 Disposable Pens
  • 5.2 Drugs
    • 5.2.1 Oral Anti-Diabetes Drugs
    • 5.2.2 Insulin Drugs
    • 5.2.3 Combination Drugs
    • 5.2.4 Non-Insulin Injectable Drugs

6. Market Indicators

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Medtronic
    • 7.1.3 Insulet
    • 7.1.4 Tandem
    • 7.1.5 Ypsomed
    • 7.1.6 Novartis
    • 7.1.7 Sanofi
    • 7.1.8 Eli Lilly
    • 7.1.9 Abbottt
    • 7.1.10 Roche
    • 7.1.11 Astrazeneca
    • 7.1.12 Dexcom
    • 7.1.13 Pfizer
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

India Diabetes Drugs and Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be given several times a day, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections, such as insulin. The India diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices (management devices such as insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices including self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.

Devices Monitoring Devices Self-monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices Insulin Pump
Insulin Syringes
Insulin Cartridges
Disposable Pens
Drugs Oral Anti-Diabetes Drugs
Insulin Drugs
Combination Drugs
Non-Insulin Injectable Drugs
Need A Different Region or Segment?
Customize Now

Frequently Asked Questions

What is the current undefined size?

The undefined is projected to register a CAGR of greater than 3% during the forecast period (2025-2030)

Who are the key players in undefined?

Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the undefined.

What years does this undefined cover?

The report covers the undefined historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the undefined size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

India Diabetes Drugs and Devices Industry Report

Statistics for the 2025 India Diabetes Drugs and Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. India Diabetes Drugs and Devices analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.